US Patent Issued to SHANDONG XUANZHU PHARMA, XUANZHU BIOPHARMACEUTICAL on Oct. 14 for "Crystal form of polycyclic anaplastic lymphoma kinase inhibitor" (Chinese Inventors)

ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,441,717, issued on Oct. 14, was assigned to SHANDONG XUANZHU PHARMA Co. LTD. (Jinan, China) and XUANZHU BIOPHARMACEUTICAL Co. LTD. (Shijiazhuang, China).

"Crystal form of polycyclic anaplastic lymphoma kinase inhibitor" was invented by Guohui Han (Jinan, China) and Haibo Wang (Jinan, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a crystal form of a polycyclic anaplastic lymphoma kinase inhibitor and a preparation method therefor, a pharmaceutical composition comprising the crystal form, and use of the crystal form or the pharmaceutical composition. Specifically, the present invention relates to a crystal form of a...